Nastech Announces Multi-Compound Agreement with Novo Nordisk
News Mar 20, 2006
Nastech Pharmaceutical Company Inc. has announced that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.
"Nastech is honored to be working with Novo Nordisk, a world-leader in therapies for metabolic disease," said Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.
"Novo Nordisk is known for its ethical standards and has participated in many innovative advances in medical practice."